Sutton Wealth Advisors’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-1,657
Closed -$33.7K 975
2022
Q4
$33.7K Buy
1,657
+11
+0.7% +$276 0.01% 513
2022
Q3
$42.2K Buy
1,646
+18
+1% +$482 0.02% 416
2022
Q2
$38.7K Sell
1,628
-11
-0.7% -$240 0.02% 451
2022
Q1
$36.9K Buy
1,639
+144
+10% +$3.06K 0.01% 499
2021
Q4
$29.6K Sell
1,495
-135
-8% -$2.74K 0.01% 586
2021
Q3
$32.1K Buy
1,630
+159
+11% +$3.33K 0.01% 532
2021
Q2
$32.4K Hold
1,471
0.01% 545
2021
Q1
$35K Hold
1,471
0.01% 496
2020
Q4
$38.5K Hold
1,471
0.02% 428
2020
Q3
$25.6K Buy
1,471
+240
+19% +$3.83K 0.01% 475
2020
Q2
$20.7K Hold
1,231
0.01% 519
2020
Q1
$14.6K Sell
1,231
-474
-28% -$5.87K 0.01% 552
2019
Q4
$20.6K Hold
1,705
0.01% 594
2019
Q3
$24.1K Buy
+1,705
New +$21K 0.01% 517
2019
Q2
Sell
-1,382
Closed -$16.2K 1177
2019
Q1
$16.2K Sell
1,382
-178
-11% -$2.21K 0.01% 650
2018
Q4
$20.8K Buy
1,560
+239
+18% +$3.16K 0.01% 511
2018
Q3
$18.5K Buy
+1,321
New +$18.5K 0.01% 617
2018
Q2
Sell
-1,383
Closed -$22.8K 1137
2018
Q1
$22.8K Buy
+1,383
New +$25.6K 0.02% 521

Other funds holding CORT

Sutton Wealth Advisors's CORT Position: Q1 2023 in Review

Sutton Wealth Advisors sold out of Corcept Therapeutics (CORT) in Q1 2023, closing a stake of 1,657 shares — an estimated $33.7K sold.

Sutton Wealth Advisors first reported a position in CORT in Q1 2018 and held it in 18 quarters. The position peaked at $42.2K in Q3 2022. 232 funds tracked by Wall St. Rank hold CORT as of Q1 2023.

  • Sutton Wealth Advisors reported no remaining Corcept Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Sutton Wealth Advisors sold 1,657 Corcept Therapeutics shares in Q1 2023, an estimated $33.7K.
  • Sutton Wealth Advisors first reported a position in Corcept Therapeutics in Q1 2018 and held it in 18 quarters.
  • Sutton Wealth Advisors's Corcept Therapeutics position peaked at $42.2K in Q3 2022.
  • 232 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2023.

Based on Sutton Wealth Advisors's 13F filing for Q1 2023, filed 7 Nov 2023.